Prospective Registrational Trial to Define Real World Outcomes of Patients with Completely Resected Stage I or IIA Non-squamous Non-Small Cell Lung Cancer NSCLC Identified as High, Intermediate, or Low Risk by a 14-Gene Prognostic Assay, DetermaRXTM, being Considered for Adjuvant Platinum-based chemotherapy or other Adjuvant therapy versus Observation

Brief Summary

Type:
Lung Cancers

Study Type:
Supportive Care

Phase:
IV

ClinicalTrials.gov Identifier:
NCT05032352

Study #:
STUDY00148066

Start Date:
Jul 19, 2022

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05032352

View Complete Trial Details & Eligibility at ClinicalTrials.gov